Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01772953 · ClinicalTrials.gov registry record · Phase 2

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

A Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), sponsored by Center for International Blood and Marrow Transplant Research.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
20
Study locations

NCT01772953: Completed Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), sponsored by Center for International Blood and Marrow Transplant Research.

NCT01772953 is a Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 40 participants, below the 144-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01772953, a Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), has completed, sponsored by Center for International Blood and Marrow Transplant Research.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, open-label, nonrandomized, prospective clinical trial evaluating a fixed regimen of treosulfan, fludarabine and low-dose total body irradiation (TBI) in children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). The primary hypothesis is that HCT with a preparative regimen consisting of treosulfan, fludarabine and low-dose TBI will result in overall survival (OS) comparable to historical rates observed with conventional myeloablative regimens in the pediatric population. The preparative regimen will result in adequate incidence of neutrophil and platelet engraftment, and acceptable rates of graft-versus-host disease (GVHD), relapse and survival. The pharmacokinetic (PK) profile of treosulfan in children will be comparable to that of adults previously studied.

Primary Outcome

The primary objective of this study is to determine the safety and preliminary efficacy of a transplant preparative regimen consisting of treosulfan, fludarabine and low-dose TBI for children with AML and MDS. The primary endpoint will be overall survival (OS) at one year.

Conditions Studied

Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

Interventions

  • DRUG Treosulfan

Study Locations (20)

Ohio

  • University Hospitals Case Medical Center - Cleveland
  • Cleveland Clinic - Cleveland
  • Nationwide Children's Hospital - Columbus

California

  • City of Hope - Duarte
  • Children's Hospital Los Angeles - Los Angeles

Missouri

  • Children's Mercy Hospital - Kansas City
  • Washington University, St. Louis Children's - St Louis

Alabama

  • Children's Hospital of Alabama/UAB - Birmingham

Arizona

  • Phoenix Children's Hospital - Phoenix

Colorado

  • Children's Hospital of Colorado - Aurora

District of Columbia

  • Children's National Medical Center - Washington D.C.

Florida

  • All Children's Hospital - St. Petersburg

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2013-09
Est. Completion 2015-08
Phase Phase 2
Center for International Blood and Marrow Transplant Research

29 total trials

What the finished NCT01772953 record still lists

NCT01772953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 144-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (72% lower).

The record links to 2 conditions, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 1 intervention - of which Treosulfan is the first listed.

NCT01772953 names 20 study sites across 16 states, led by Ohio, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT01772953 about?

NCT01772953 is a clinical study titled "Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT". This is a prospective, open-label, nonrandomized, prospective clinical trial evaluating a fixed regimen of treosulfan, fludarabine and low-dose total body irradiation (TBI) in children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell trans...

What is the current status of trial NCT01772953?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2013-09. Estimated completion is 2015-08.

What conditions does trial NCT01772953 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS).

What interventions are being tested in trial NCT01772953?

The interventions under investigation include: Treosulfan (DRUG).

Who is sponsoring clinical trial NCT01772953?

This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01772953 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia (AML)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01772953's enrollment target sits among peer trials

40 20th of 29 higher than 10 of 29 other Acute Myeloid Leukemia (AML) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia (AML) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01772953, the US trial registry maintained by the National Library of Medicine. NCT01772953 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.